Stockholm, Sweden — Medivir AB (OMX: MVIR) announces a good market uptake and strong sales development for simeprevir during the first quarter 2014. In light of this, Johnson & Johnson and Medivir are now disclosing the simeprevir sales in conjunction with Johnson & Johnson’s first quarter report 2014.
Help employers find you! Check out all the jobs and post your resume.
